Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Elobixibat Hydrate: Selective IBAT Inhibitor for Chronic ...

    2026-04-07

    Elobixibat Hydrate: Selective IBAT Inhibitor for Chronic Constipation and Metabolic Modulation

    Executive Summary: Elobixibat hydrate is a potent, selective inhibitor of the ileal bile acid transporter (IBAT), primarily used to treat chronic idiopathic constipation and to improve metabolic parameters in type 2 diabetes mellitus (T2DM) (APExBIO product dossier). The drug increases colonic bile acid concentrations, activating TGR5 and promoting GLP-1 secretion, resulting in enhanced colonic motility and metabolic effects ([Elobixibat Hydrate: Mechanistic Leverage and Strategic Op...](https://tenapanorshop.com/index.php?g=Wap&m=Article&a=detail&id=93)). Clinical use demonstrates increased spontaneous bowel movements, improved stool consistency, and reduced LDL cholesterol and HbA1c. Elobixibat hydrate exhibits low systemic bioavailability, high protein binding, and a short half-life, with generally mild gastrointestinal adverse effects. This article integrates recent clinical and mechanistic data, extending and clarifying prior resources (see contrast).

    Biological Rationale

    Chronic idiopathic constipation affects up to 14% of the general population and is associated with impaired colonic transit and decreased bowel motility ([Elobixibat Hydrate: Selective IBAT Inhibitor for Chronic ...](https://sitagliptinonline.com/index.php?g=Wap&m=Article&a=detail&id=92)). The ileal bile acid transporter (IBAT, also known as SLC10A2) mediates reabsorption of bile acids in the terminal ileum, regulating enterohepatic circulation. Disrupted bile acid homeostasis is implicated in constipation, metabolic syndrome, and T2DM. Pharmacological inhibition of IBAT increases bile acid delivery to the colon, stimulating secretion and peristalsis via TGR5 receptor activation and GLP-1 release. These pathways are central to the therapeutic rationale for elobixibat hydrate. APExBIO supplies elobixibat hydrate (SKU C8720) for research and clinical applications (APExBIO elobixibat product page).

    Mechanism of Action of Elobixibat hydrate

    Elobixibat hydrate (CAS No. 1633824-78-8), also known as A 3309 hydrate or AZD 7806 hydrate, is a small molecule oral inhibitor of IBAT/SLC10A2. By blocking IBAT in the ileal mucosa, elobixibat reduces bile acid reabsorption, leading to increased concentrations of bile acids in the colon. This rise in luminal bile acids activates the G protein-coupled bile acid receptor TGR5, which in turn promotes the secretion of glucagon-like peptide-1 (GLP-1) from enteroendocrine L cells. GLP-1 enhances colonic secretion and motility, and improves glucose and lipid metabolism. The drug exhibits low systemic bioavailability, with plasma concentrations in the picomolar range and protein binding above 99%. Its reported half-life is less than 4 hours, supporting once-daily oral dosing.

    Evidence & Benchmarks

    • Elobixibat hydrate increases spontaneous bowel movements (SBMs) by ≥3/week in adults with chronic idiopathic constipation (CIC) (see APExBIO dossier).
    • Treatment improves stool consistency (Bristol Stool Form Scale score rise ≥1) after a single 10 mg oral dose (APExBIO).
    • Reductions in HbA1c by approximately 0.2% and LDL cholesterol by 21.4 mg/dL observed in T2DM cohorts (APExBIO; internal dossier).
    • Low systemic exposure: plasma levels in picomolar range; protein binding >99%; half-life <4 h (APExBIO).
    • Adverse effects generally mild: abdominal pain, distension, and diarrhea; no serious safety concerns reported (DOI:10.1080/23744235.2023.2200563).

    Applications, Limits & Misconceptions

    Elobixibat hydrate is approved for the treatment of chronic idiopathic constipation and is used as a bowel preparation adjunct prior to colonoscopy. Its ability to lower LDL cholesterol and HbA1c extends its use to patients with comorbid T2DM and metabolic dysregulation. The compound's low systemic absorption and high protein binding reduce potential for systemic side effects. Solubility is high in DMSO (≥49.2 mg/mL) and in ethanol with ultrasonic assistance (≥9.82 mg/mL), but it is insoluble in water. Product should be stored sealed and dried at 4°C.

    Common Pitfalls or Misconceptions

    • Elobixibat hydrate is not indicated for acute constipation or for patients with bowel obstruction.
    • The drug does not exert antimicrobial effects or modulate immune responses directly.
    • Systemic metabolic effects are modest; HbA1c and LDL reductions should not be considered primary therapeutic endpoints.
    • It is not interchangeable with non-selective laxatives or other bile acid sequestrants.
    • The compound is not effective in patients with severe hepatic impairment due to altered bile acid metabolism.

    This article extends prior summaries by providing precise solubility, pharmacokinetic, and adverse event data, clarifying boundaries for use ([Elobixibat Hydrate: Strategic Advances in Enterohepatic M...](https://sitagliptinonline.com/index.php?g=Wap&m=Article&a=detail&id=74)).

    Workflow Integration & Parameters

    Researchers and clinicians should use elobixibat hydrate at standard doses (10 mg/day orally for constipation and T2DM; single 10 mg dose for colonoscopy prep), adjusting for clinical context. For in vitro work, dissolve in DMSO or ethanol as per solubility data. For translational and experimental workflows, consult the C8720 kit guide. Comparative protocol details and troubleshooting strategies are discussed in this internal article, which focuses on practical laboratory assay integration and product selection.

    Conclusion & Outlook

    Elobixibat hydrate represents a validated, selective IBAT inhibitor with applications in chronic idiopathic constipation and metabolic modulation in T2DM. Its mechanism via TGR5 activation and GLP-1 secretion is well characterized, with robust efficacy and safety data. Ongoing research may expand indications and refine dosing strategies. For the most current protocols and sourcing, refer to APExBIO's product page. For a systems-level research roadmap, see this comparative perspective, which offers a broader translational context beyond clinical summaries.